SIK2 and melanoma: Because 4′-O-methylfisetin did not activate ERK in B16F10 melanoma cells, the upregulation of TORC activity by SIK2 inhibition has been suggested be a beneficial strategy for the treatment of neuronal diseases, and fisetin or 4′-O-methylfisetin may be helpful to perform this strategy.